Nuwiq 4000 IU powder and solvent for solution for injection

DRUG3 trials

Sponsors

Octapharma AG, HZRM Haemophilie-Zentrum Rhein Main GmbH, Emory University

Conditions

Haemophilia A

Phase 4

Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis study (NuPOWER)

RecruitingCTIS2022-502060-21-00

Octapharma AGHaemophilia A

Start: 2023-10-19Target: 45Updated: 2025-09-25

Nuwiq Dosing and outcomes In the ManagEment of women/girls with haemophilia A Needing FVIII treatment for Surgery – an International, Open-label, Non-controlled study (NuDIMENSION)

RecruitingCTIS2022-502061-17-00

Octapharma AGHaemophilia A

Start: 2023-12-15Target: 17Updated: 2025-12-22

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A – An International Low-Interventional Pragmatic Investigator Initiated Trial

RecruitingCTIS2024-516741-39-00

HZRM Haemophilie-Zentrum Rhein Main GmbH, Emory UniversityHaemophilia A

Start: 2020-01-14Target: 22Updated: 2025-10-28

Related Papers

NuPOWER (Nuwiq for Perioperative management Of patients With haemophilia A on Emicizumab Regular prophylaxis): protocol for an open-label, single-arm, multicentre study.

2025-10-28

Design of an international, phase IV, open-label study of simoctocog alfa in women/girls with hemophilia A undergoing surgery (NuDIMENSION).

2024-12-01